FDA
-
-
-
-
-
-
-
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
-
-
-
-
-
-
-
Protara Therapeutics begins phase 3 trial of IV choline chloride
-
-
-
-
-
-
-
Protara Therapeutics schedules call on TARA-002 trial data
-
-
-
-
-
-
-
Protara to present TARA-002 trial data at oncology conference
-
-
-
-
-
-
-
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
-
-
-
-
-
-
-
Protara Therapeutics (TARA) to present phase 2 analysis of TARA-002 trial
-
-
-
-
-
-
-
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

